Patents by Inventor Karen Gray

Karen Gray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100021469
    Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have show that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was show by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
    Type: Application
    Filed: September 29, 2009
    Publication date: January 28, 2010
    Inventors: Frank Cuttitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William A. Hook, Thomas Walsh, Karen Gray, Charles Macri
  • Publication number: 20070020278
    Abstract: Methods for treating or diagnosing cancers of the female reproductive tract and childhood cancers are disclosed. The methods described herein use binding agents, e.g., antibodies, specific for the extracellular domain of human prostate specific membrane antigen (PSMA).
    Type: Application
    Filed: September 28, 2006
    Publication date: January 25, 2007
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.*EWC*
    Inventors: Jeffrey Ross, Karen Gray
  • Publication number: 20070004630
    Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have show that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was show by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
    Type: Application
    Filed: September 5, 2006
    Publication date: January 4, 2007
    Inventors: Frank Cuttitta, Alfredo Martinez, Mae Miller, Edward Unsworth, William Hook, Thomas Walsh, Karen Gray, Charles Macri
  • Patent number: 7101548
    Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: September 5, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Frank Cuttitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William Hook, Thomas Walsh, Karen Gray, Charles Macri
  • Publication number: 20050202020
    Abstract: Methods for treating or diagnosing cancers of the female reproductive tract and childhood cancers are disclosed. The methods described herein use binding agents, e.g., antibodies, specific for the extracellular domain of human prostate specific membrane antigen (PSMA).
    Type: Application
    Filed: December 30, 2004
    Publication date: September 15, 2005
    Inventors: Jeffrey Ross, Karen Gray
  • Publication number: 20050156902
    Abstract: An electronic viewing tablet is provided with a uni-body display and touch screen system. The device includes a large display, connectors for USB, flash ROM ports (such as Smart Media, Compact Flash and Secure Digital/Multi-Media Flash) protected behind a waterproof access door, a wireless network interface, a momentary contact switch and a waterproof access panel for servicing the internal battery. An inductive charging system may be provided to recharge an internal battery. A microprocessor based electronic communication and control system controls the electronic components of the device. The electronic tablet allows a user to acquire content and applications on a personal computer or network or purchase data and images on removable flash media. Applications, data and images (electronic books, magazines, newspapers, text files, sheet music and “printed” files) may be downloaded to the tablet through a USB connector, a wireless connection, or through a ROM port.
    Type: Application
    Filed: January 20, 2004
    Publication date: July 21, 2005
    Inventors: Roger McPherson, Karen Gray, James Wood
  • Publication number: 20020055615
    Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for Tpeptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
    Type: Application
    Filed: August 16, 2001
    Publication date: May 9, 2002
    Inventors: Frank Cuttitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William Hook, Thomas Walsh, Karen Gray, Charles Macri
  • Patent number: 6320022
    Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
    Type: Grant
    Filed: February 17, 1998
    Date of Patent: November 20, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Frank Cutitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William Hook, Thomas Walsh, Karen Gray, Charles Macri